Cancer drug developer Juno's shares soar 65 pct in debut | Business Information & News | Westlaw

Cancer drug developer Juno's shares soar 65 pct in debut | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Cancer drug developer Juno's shares soar 65 pct in debut, Business Information & News
12/19/14 REUTERS 17:39:28
REUTERS
Copyright © 2014 Thomson Reuters
December 19, 2014
Cancer drug developer Juno's shares soar 65 pct in debut
(Reuters) - Shares of cancer drug developer Juno Therapeutics Inc soared as much as 65 percent in their market debut on Friday, capping a big year for biotech IPOs.
Early tests have shown strong results for Juno's experimental immunotherapy, which...
---- Index References ----
Company: BELLICUM PHARMACEUTICALS INC; AMAZON COM INC; MORGAN STANLEY; JPMORGAN CHASE AND CO; KITE PHARMA INC; JUNO THERAPEUTICS INC; GOLDMAN SACHS GROUP INC (THE)
News Subject: (Equity Instruments (1EQ90); Health & Family (1HE30); Funding Instruments (1FU41); Stock Offerings (1ST44); Initial Public Offerings (IPOs) (1IN65); Corporate Funding (1XO17))
Industry: (Oncology & Hematology (1ON95); Healthcare Practice Specialties (1HE49); Cancer Drugs (1CA21); Internal Medicine (1IN54); Healthcare (1HE06); Investment Management (1IN34); Financial Services (1FI37); Drugs (1DR89); Pharmaceuticals & Biotechnology (1PH13); Securities Investment (1SE57))
Language: EN
Other Indexing: (Jeff Bezos)
Keywords: securities; capmarket; SecOfferings (MCC:f); (N2:US); (N2:AMERS); (N2:USA); (MCCL:OVR); (MCCL:OEC)
Word Count: 260
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.